J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Subscribe To Our Newsletter & Stay Updated